ARCA biopharma Reports Director/Officer Changes, Shareholder Vote
Ticker: ORKA · Form: 8-K · Filed: Jan 31, 2024 · CIK: 907654
| Field | Detail |
|---|---|
| Company | Arca Biopharma, Inc. (ORKA) |
| Form Type | 8-K |
| Filed Date | Jan 31, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $1.64 |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: corporate-governance, executive-changes, shareholder-vote
TL;DR
**ARCA biopharma just filed an 8-K about leadership changes and a shareholder vote, signaling potential shifts.**
AI Summary
ARCA biopharma, Inc. filed an 8-K on January 31, 2024, reporting events that occurred on January 30, 2024. The filing indicates that the company will be submitting matters to a vote of security holders and includes information about the departure or election of directors and officers, as well as their compensatory arrangements. This matters to investors because changes in leadership and executive compensation, along with shareholder votes, can signal strategic shifts or governance issues that impact future company performance and stock value.
Why It Matters
Changes in company leadership and executive compensation can directly influence strategic direction and operational efficiency, impacting investor confidence and stock performance. Shareholder votes on key matters can also dictate the company's future path.
Risk Assessment
Risk Level: medium — Changes in leadership and upcoming shareholder votes introduce uncertainty regarding future company direction and stability, which can impact stock value.
Analyst Insight
A smart investor would monitor ARCA biopharma's upcoming proxy statements for details on the shareholder vote and the specifics of the director/officer changes and compensation arrangements to understand the strategic implications before making investment decisions.
Key Players & Entities
- ARCA biopharma, Inc. (company) — the registrant filing the 8-K
- January 31, 2024 (date) — date of 8-K filing
- January 30, 2024 (date) — date of earliest event reported
- 000-22873 (other) — Commission File Number
- 36-3855489 (other) — IRS Employer Identification No.
FAQ
What specific items were reported in this 8-K filing by ARCA biopharma, Inc.?
The 8-K filing by ARCA biopharma, Inc. reported on three specific items: 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers', 'Submission of Matters to a Vote of Security Holders', and 'Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 30, 2024, as stated in the 'Date of Report (Date of earliest event reported): January 31, 2024 (January 30, 2024)' section.
What is the business address of ARCA biopharma, Inc. as listed in the filing?
The business address of ARCA biopharma, Inc. is 10170 Church Ranch Way, Suite 100, Westminster, Colorado, 80021, according to the filing.
What is the telephone number for ARCA biopharma, Inc.?
The registrant's telephone number, including area code, is (720) 940-2200, as provided in the filing.
Under which SEC Act was this 8-K filed?
This 8-K was filed under the 1934 Act, as indicated in the 'FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act' section.
Filing Stats: 810 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-01-31 16:15:13
Key Financial Figures
- $1.64 — (the "Options") at an exercise price of $1.64 per share, the closing price of the Com
Filing Documents
- abio-20240130.htm (8-K) — 62KB
- 0000950170-24-009397.txt ( ) — 174KB
- abio-20240130.xsd (EX-101.SCH) — 24KB
- abio-20240130_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On January 30, 2024, the Company held the 2023 Annual Meeting of Stockholders at which the Company's stockholders voted upon (i) the election of Company nominees, Dr. Michael R. Bristow and Mr. Robert E. Conway, to the Board for a three-year term ending at the 2026 Annual Meeting of Stockholders, (ii) the ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 and (iii) the approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Company's Proxy Statement filed with the Securities and Exchange Commission on December 19, 2023. The stockholders elected the director nominees, ratified the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, and approved the resolution concerning the advisory vote on the compensation of the Company's named executive officers. The tabulation of votes cast with respect to each matter voted upon, as applicable, was as follows: 1. Election of Directors: Nominee For Withheld Broker Non-Votes Dr. Michael R. Bristow 6,952,545 1,088,323 2,577,852 Mr. Robert E. Conway 6,758,409 1,282,459 2,577,852 2. Ratification of the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstentions Broker Non-Votes 10,286,650 263,929 68,141 — 3. Executive Compensation: For Against Abstentions Broker Non-Votes 6,548,473 1,472,454 19,941 2,577,852
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCA biopharma, Inc. (Registrant) Date: January 31, 2024 By: /s/ C. Jeffrey Dekker Name: C. Jeffrey Dekker Title: Chief Financial Officer